Ghent, Belgium

Vladimir Bobkov

This inventor holds 2 USPTO granted patents and 5 published patent applications. Top assignee: Argenx Bv. Active years: 2025-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Vladimir Bobkov: Innovator in FcRn/HSA Binding Molecules

Introduction

Vladimir Bobkov is a notable inventor based in Ghent, Belgium. He has made significant contributions to the field of biochemistry, particularly in the development of binding molecules that have potential therapeutic applications.

Latest Patents

One of his key patents is focused on FcRn/HSA binding molecules and methods of use. This patent describes binding molecules that comprise a human neonatal Fc receptor (FcRn) binding molecule and at least one antigen-binding domain linked to the FcRn binding molecule. Additionally, it includes polynucleotides, vectors, host cells, and methods of production. The patent also outlines methods for treating antibody-mediated disorders using an FcRn/antigen-binding molecule.

Career Highlights

Vladimir Bobkov is currently associated with Argenx BV, a company known for its innovative approaches in the field of immunology. His work has led to advancements that could significantly impact the treatment of various medical conditions.

Collaborations

He collaborates with talented individuals such as Karen Silence and Jolien Van Santbergen, contributing to a dynamic research environment that fosters innovation.

Conclusion

Vladimir Bobkov's work in developing FcRn/HSA binding molecules showcases his commitment to advancing medical science. His contributions are paving the way for new treatment options in antibody-mediated disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…